DRUG METABOLISM AND DISPOSITION
Scope & Guideline
Elevating Knowledge in Drug Metabolism and Disposition
Introduction
Aims and Scopes
- Pharmacokinetics and Drug Disposition:
Research articles often explore the pharmacokinetics of drugs, including absorption, distribution, metabolism, and excretion (ADME). This encompasses both in vivo and in vitro studies, utilizing physiologically based pharmacokinetic modeling to predict human responses. - Drug-Metabolizing Enzymes:
A key focus is on cytochrome P450 enzymes and other drug-metabolizing enzymes, examining their roles in drug metabolism, genetic polymorphisms, and variations in enzymatic activity across different populations. - Transport Mechanisms:
The journal highlights studies on drug transporters, including their regulation, function, and impact on drug absorption and disposition, emphasizing the interplay between metabolic enzymes and transport systems. - Toxicology and Drug Safety:
Research often addresses the toxicological aspects of drug metabolism, including the identification of metabolites that may contribute to adverse drug reactions and strategies for mitigating these effects. - Clinical Relevance and Biomarkers:
The journal emphasizes the clinical implications of drug metabolism research, including the identification of biomarkers for drug efficacy and safety, and the impact of genetic and environmental factors on individual drug responses. - Innovative Methodologies:
The use of novel experimental approaches, such as high-throughput screening, advanced analytical techniques, and computational modeling, is frequently reported to enhance our understanding of drug metabolism and disposition.
Trending and Emerging
- Precision Medicine and Pharmacogenomics:
There is an increasing emphasis on precision medicine and pharmacogenomics, as studies investigate how genetic variations affect drug metabolism, efficacy, and safety, paving the way for individualized therapeutic strategies. - Physiologically Based Pharmacokinetic (PBPK) Modeling:
The use of PBPK modeling is on the rise, allowing for more accurate predictions of drug behavior in humans based on in vitro data, enhancing the relevance of preclinical studies to clinical outcomes. - Gut Microbiome Interactions:
Emerging research on the role of the gut microbiome in drug metabolism is gaining traction, highlighting how microbial metabolites can influence drug efficacy and toxicity. - Transporter Biology and Drug Disposition:
There is a growing focus on the roles of transporters in drug absorption and disposition, particularly how they interact with metabolic enzymes and their implications for drug-drug interactions. - Innovative Drug Delivery Systems:
Research into novel drug delivery systems, such as nanoparticles and liposomal formulations, is trending, reflecting a broader interest in optimizing drug bioavailability and therapeutic outcomes. - Environmental and Dietary Influences:
Recent studies are increasingly examining how environmental factors and dietary components affect drug metabolism, emphasizing the importance of lifestyle in pharmacokinetic profiles.
Declining or Waning
- Traditional In Vitro Models:
There seems to be a waning interest in conventional in vitro models for drug metabolism, such as using only liver microsomes or hepatocytes, as researchers increasingly adopt more sophisticated systems like 3D cell cultures or organ-on-chip technologies. - Non-Cytochrome P450 Enzyme Studies:
Research specifically focused on non-cytochrome P450 enzymes appears to be less frequent, suggesting a shift towards more detailed investigations of cytochrome P450 enzymes and their interactions with other metabolic pathways. - General Drug Interaction Studies:
There is a noticeable decline in the publication of generic drug-drug interaction studies without a specific focus on mechanisms, as the field moves towards more nuanced explorations of specific pathways and genetic influences. - Animal Models for Drug Metabolism:
The reliance on traditional animal models for drug metabolism studies is decreasing, with a growing emphasis on humanized models and in vitro systems that better predict human responses. - Historical Perspectives:
Papers providing broad historical overviews on drug metabolism topics are becoming less common, indicating a shift towards more focused, cutting-edge research that addresses current challenges in drug metabolism and pharmacokinetics.
Similar Journals
XENOBIOTICA
Innovating Insights into Chemical Substances and Life.XENOBIOTICA is a premier journal in the field of pharmacology and toxicology, published by Taylor & Francis Ltd. With an ISSN of 0049-8254 and E-ISSN 1366-5928, this journal has been at the forefront of research since 1971, providing critical insights and advancements up until 2024. It is recognized for its rigorous peer-reviewed content, occupying a third quartile ranking across various categories including Biochemistry, Health, Toxicology, and Pharmacology as of 2023. The journal serves as a pivotal platform for disseminating innovative findings that address the impact of xenobiotics on health and the environment, making it an essential resource for researchers, professionals, and students engaged in these multidisciplinary fields. While it does not currently offer open access, it is widely respected for its contribution to science, evidenced by its Scopus rankings across different areas of study. The journal encourages submissions that push the boundaries of knowledge and transform our understanding of the effects of chemical substances on living organisms.
BMC Pharmacology & Toxicology
Fostering collaboration in pharmacology and toxicology.Welcome to BMC Pharmacology & Toxicology, a premier open-access journal dedicated to advancing the fields of pharmacology and toxicology. Published by BMC since 2012, this esteemed journal offers a platform for researchers, professionals, and students to disseminate cutting-edge research and innovative findings that explore the intricate interactions between drugs and biological systems. With its robust Q2 ranking in both general medicine and pharmacology categories for 2023, BMC Pharmacology & Toxicology is recognized for its significant contributions to the academic community, reflected in its strategic positioning within the 61st and 49th percentiles in Scopus rankings for related disciplines. The journal's commitment to open access ensures that vital research is accessible to a global audience, fostering collaboration and informed discussions. We invite you to engage with the latest studies, reviews, and innovative methodologies that shape the future of pharmacological and toxicological sciences.
DRUG METABOLISM REVIEWS
Unraveling the complexities of drug interactions.Drug Metabolism Reviews is a premier journal dedicated to the dissemination of scientific research and reviews in the field of pharmacology, toxicology, and pharmaceutics, published by Taylor & Francis Ltd. With its inception dating back to 1972, this journal has consistently provided an authoritative platform for scholars and professionals from diverse disciplines to explore the intricate mechanisms of drug metabolism and their implications for therapeutic applications. The journal enjoys commendable rankings, placing in the Q2 quartile for Pharmacology (medical) and the Q1 quartile in the miscellaneous subfield, signaling its significant impact within the community. Notably, it is recognized within the top 96th percentile in General Pharmacology, Toxicology and Pharmaceutics, affirming its esteemed position among academic publications. Although it operates under a subscription model, Drug Metabolism Reviews remains an essential resource for researchers, professionals, and students seeking to deepen their understanding of drug interactions, safety, and efficacy. The insights shared within its pages contribute vital knowledge to the global discourse on drug development and personalized medicine.
Drug Metabolism and Pharmacokinetics
Shaping the Future of Therapeutics Through Metabolism InsightsDrug Metabolism and Pharmacokinetics is a premier academic journal committed to advancing the understanding of drug metabolism processes and pharmacokinetic principles critical to the development of therapeutics. Published by the Japanese Society for the Study of Xenobiotics, this journal has established itself as a vital resource within Pharmaceutical Science and Pharmacology, achieving a respectable Q2 ranking in the latest 2023 metrics. Spanning from 2002 to 2024, the journal publishes original research articles, reviews, and insights that address contemporary issues in xenobiotic metabolism and pharmacologic practices. With its ISSN of 1347-4367 and E-ISSN of 1880-0920, Drug Metabolism and Pharmacokinetics is indexed in leading databases, enhancing its visibility and accessibility for researchers, professionals, and students alike. By fostering a rigorous scientific dialogue, the journal plays an essential role in shaping the future of pharmacology and pharmaceutical sciences.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
Connecting Experimental Insights with Clinical ApplicationsCLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, published by WILEY, is a premier journal that serves as a vital resource for researchers, professionals, and students in the fields of pharmacology and physiology. With ISSN 0305-1870 and E-ISSN 1440-1681, this journal has established itself as a significant contributor to scientific dialogue since its inception in 1974. Currently spanning until 2024, it consistently publishes cutting-edge research addressing both experimental and clinical advancements in pharmacology and physiology. Recognized for its quality, it holds a Q2 ranking in the 2023 Pharmacology category and notable Q3 rankings in both Physiology and Medical Physiology. The journal's coverage of topical issues not only ensures a robust platform for innovative findings but also fosters collaborations across disciplines. Although not an Open Access journal, its curated content is invaluable for advancing knowledge, as evidenced by its solid Scopus rankings, which place it within the top percentiles of its field. Engaging with this journal means staying at the forefront of research that shapes clinical practices and experimental methodologies.
PHARMAZIE
Bridging research and practice in pharmacology.PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
Unveiling New Horizons in Pharmacology and Drug DevelopmentASSAY AND DRUG DEVELOPMENT TECHNOLOGIES is a peer-reviewed journal published by Mary Ann Liebert, Inc., focused on the innovative fields of pharmacology and drug development. With its ISSN 1540-658X and E-ISSN 1557-8127, the journal has successfully contributed to the scientific community since its inception in 2002, converging into one comprehensive resource by 2024. Positioned in the Q3 quartile for Drug Discovery and Q4 for Molecular Medicine as per the 2023 rankings, the journal is dedicated to disseminating cutting-edge research that addresses the complexities of drug assay techniques and their implications in therapeutics. Although currently not an open-access publication, it offers significant insights and findings valuable to researchers, professionals, and students in the realm of biochemistry and pharmacology. With a commitment to advancing knowledge and innovation, ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES continues to be an essential platform for the latest advancements in drug discovery and development.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
Connecting Research to Real-World ApplicationsJOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, published by Springer/Plenum Publishers, stands as a vital resource in the field of pharmacology. With an ISSN of 1567-567X and an E-ISSN of 1573-8744, this journal is well-regarded within the academic community, as reflected in its Q2 ranking in the 2023 Scopus category for Pharmacology. Spanning years from 1996 to 2024, it serves as a comprehensive platform for cutting-edge research on the interactions of drugs within the body, their effects, and the underlying pharmacological mechanisms. The journal provides a critical avenue for dissemination of significant research findings, with a focus on enhancing understanding in pharmacokinetics, pharmacodynamics, and their implications in therapeutic practices. Targeting an audience of researchers, professionals, and students, the journal emphasizes high-quality manuscripts that contribute to the advancement of knowledge in pharmacology. Although currently not an open access journal, it maintains a strong commitment to promoting scientific communication and collaboration.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Pioneering research at the intersection of chemotherapy and oncology.Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.
CURRENT DRUG METABOLISM
Advancing the Frontiers of Drug ResearchCURRENT DRUG METABOLISM, published by Bentham Science Publishers Ltd, serves as a pivotal resource in the fields of Clinical Biochemistry and Pharmacology. With an ISSN of 1389-2002 and an E-ISSN of 1875-5453, this journal has carved a niche since its inception in 2000, offering in-depth research and reviews that bridge the gap between drug metabolism and its clinical applications. The journal finds itself positioned in the third quartile (Q3) for both Clinical Biochemistry and Pharmacology as of 2023, reflecting its significance within these scientific sectors, with Scopus rankings showcasing its role in advancing knowledge—rank #167 in Pharmacology and #66 in Clinical Biochemistry. Researchers and industry professionals are encouraged to contribute their findings, fostering a diverse platform that informs and inspires innovations in drug development and safety. While CURRENT DRUG METABOLISM operates under a traditional subscription model without open access, its rigorous peer-review process ensures the quality and integrity of the published work, making it indispensable for anyone engaged in drug research and biochemistry.